CASE REPORT
Published on 30 Apr 2025
Use of sintilimab in primary adenosquamous carcinoma of the liver results in pathological complete response: a case report and literature review
doi 10.3389/fimmu.2025.1578368
- Frontiers in Oncology
- Pharmacology of Anti-Cancer Drugs
- Research Topics
- Immune Checkpoints Regulatory Mechanisms and Immunotherapy Strategies in Gastrointestinal Tumors
Immune Checkpoints Regulatory Mechanisms and Immunotherapy Strategies in Gastrointestinal Tumors
1,380
Total downloads
7,032
Total views and downloads
Articles
ORIGINAL RESEARCH
Accepted on 23 Apr 2025
IL-6 is a prognostic biomarker in patients with advanced esophageal squamous cell carcinoma received with PD-1 inhibitors
doi 10.3389/fimmu.2025.1569042
CASE REPORT
Accepted on 18 Apr 2025
Immunotherapy Combined with Chemotherapy: A Promising Therapeutic Approach in the Management of Colonic Squamous Cell Carcinoma-A Case Report
doi 10.3389/fonc.2025.1548008
- 233 views
ORIGINAL RESEARCH
Accepted on 14 Apr 2025
High expression of CXCL13 predicts a favorable response to immunotherapy by upregulating CXCR5+CD8+T cell infiltration in gastric cancer
doi 10.3389/fimmu.2025.1551259
- 113 views
ORIGINAL RESEARCH
Published on 04 Apr 2025
Pembrolizumab versus bevacizumab plus modified FOLFOX6 in metastatic MSI-H/dMMR colorectal cancer: a multicenter retrospective study with CT evaluation
doi 10.3389/fonc.2025.1570457
- 645 views
ORIGINAL RESEARCH
Published on 19 Mar 2025
CXCR2P1 enhances the response of gastric cancer to PD-1 inhibitors through increasing the immune infiltration of tumors
doi 10.3389/fimmu.2025.1545605
- 763 views
ORIGINAL RESEARCH
Published on 07 Feb 2025
Combination of potassium oxonate with anti-PD-1 for the treatment of colorectal cancer
doi 10.3389/fonc.2025.1528004
- 510 views
REVIEW
Published on 30 Oct 2024
The role of PIK3CA gene mutations in colorectal cancer and the selection of treatment strategies
doi 10.3389/fphar.2024.1494802
- 2,890 views
- 2 citations
Published in
Frontiers in Oncology
Pharmacology of Anti-Cancer Drugs
Participating Journals
Frontiers in Pharmacology
- 4.4 impact factor
- 7.8 citescore